Cargando…
Phentermine-topiramate: First combination drug for obesity
Obesity is spreading globally at an alarming speed. The management of obesity is multifaceted and includes lifestyle modifications as the cornerstone. Until only orlistat was approved for long term use in obesity. The US Food and Drug Administration granted approval to a fixed dose mid 2012 combinat...
Autores principales: | Singh, Jagjit, Kumar, Rajiv |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456896/ https://www.ncbi.nlm.nih.gov/pubmed/26097830 http://dx.doi.org/10.4103/2229-516X.157177 |
Ejemplares similares
-
Phentermine and topiramate for the management of obesity: a review
por: Cosentino, Gina, et al.
Publicado: (2011) -
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
por: Shin, Jin Hee, et al.
Publicado: (2013) -
Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity
por: Jordan, Jens, et al.
Publicado: (2014) -
A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity
por: Kim, Anthony, et al.
Publicado: (2023) -
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
por: Sweeting, Arianne N, et al.
Publicado: (2014)